LLY LLY
Eli Lilly Addresses Threat of Counterfeit Oral Weight-Loss Drugs Amid Expert Warnings
Experts warn that oral weight-loss medications, easier to manufacture than injectables, could trigger a surge in counterfeit treatments. Eli Lilly's oral GLP-1...
Eli Lilly Faces Competitive Headwinds as Oral Obesity Drug Orforglipron FDA Decision is Delayed
Eli Lilly is facing increased competitive pressure in the oral GLP-1 market after the FDA delayed the decision date for its candidate, orforglipron, causing...
Eli Lilly's Oncology Drugs in Focus Ahead of Q4 2025 Earnings Report
Eli Lilly will release its fourth-quarter earnings on February 4, 2026. The company is highlighting its oncology franchise, despite continued focus on its...
Eli Lilly Stock Rises on FDA Obesity Drug Approval Momentum; Valuation Concerns Persist
Eli Lilly shares surged 3.58% to close at $1,078.52, driven by strong investor optimism surrounding the company's leading GLP-1 obesity drug portfolio...
🟢 Eli Lilly is trading 3% up today with market rebound
LLY is trading at $1074 (+3.14%) amid a broader market rebound following yesterday's tariff-driven selloff. Major indices are up modestly (S&P 500 +0.30%,...
Eli Lilly's Oncology Pipeline Receives Major FDA Breakthrough Therapy Designation
Eli Lilly received a significant boost after the U.S. FDA granted Breakthrough Therapy Designation (BTD) to a novel oncology candidate, aiming to fast-track...
Eli Lilly stock holds steady amid broad market trade war selloff
Eli Lilly stock demonstrated defensive strength on January 20, 2026, closing up 0.28% at $1,041.29, significantly outperforming the broader U.S. equity markets...
Eli Lilly holding steady amid FDA Breakthrough Therapy designation for sofetabart mipitecan and broader market decline
Eli Lilly announced that its investigational drug, sofetabart mipitecan, received FDA Breakthrough Therapy designation for the treatment of platinum-resistant...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan. The designation targets...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its drug candidate, sofetabart...
Eli Lilly announces FDA Breakthrough Therapy designation for sofetabart mipitecan in pre-market
Eli Lilly announced that the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan (LY4170156), for the treatment of...
Eli Lilly Holds Steady Amid Market Holiday; GLP-1 Dominance Supports Long-Term Outlook
Eli Lilly (LLY) maintains strong fundamental momentum driven by its dominant market position in GLP-1 medications, with analysts projecting the stock could...
Eli Lilly Solidifies Lead in Weight-Loss Drug Market Amid Fierce Competition
Eli Lilly is extending its lead over Novo Nordisk in the rapidly growing weight-loss drug market. Analysts cite the superior effectiveness of Lilly’s Zepbound...
Eli Lilly Shares Plunge Nearly 5% to Hit Four-Week Low Amid Sharp Selling Pressure
Eli Lilly shares suffered a sharp decline on January 15, falling by as much as 4.87% despite overall U.S. markets advancing during the session. The stock...
🔴 Eli Lilly is trading 3% down today after FDA delayed decision on weight-loss pill
Eli Lilly is trading at $1041.07 (-3.00%) after the FDA announced a delay in the decision timeline for its weight-loss pill. * The FDA decision on the drug...
Eli Lilly Shares Decline After FDA Delays Decision on Oral Weight-Loss Pill
The U.S. Food and Drug Administration (FDA) delayed its decision on Eli Lilly’s new oral weight-loss pill. The agency set a new target date of April 10,...
BMO Capital Markets Reiterates 'Buy' Rating on Eli Lilly, Citing Strength in Weight-Loss and Pipeline
BMO Capital Markets reaffirmed its 'outperform' rating on Eli Lilly (LLY). The firm set a $1,200 price target, suggesting a 12% upside from current...
Biogen CEO suggests potential at-home Alzheimer's therapy could challenge Lilly's Kisunla
Eli Lilly faced competitive pressure after the Biogen CEO suggested that an at-home Alzheimer's treatment could provide a significant logistical advantage over...
Eli Lilly CEO Highlights Positive Outlook at JPMorgan Healthcare Conference
Eli Lilly CEO Dave Ricks presented at the JPMorgan Healthcare Conference. The transcript became available on January 14, 2026. Ricks set a positive tone for...
Eli Lilly and Nvidia Announce $1 Billion AI Collaboration for Drug Discovery
Eli Lilly and Nvidia launched a collaboration focused on applying advanced artificial intelligence (AI) to drug development. The initiative is backed by a...